【摘要】：目的:觀察吉西他濱、奧沙利鉑聯(lián)合口服氟尿嘧啶類藥物在胰腺癌一線治療中的療效與安全性。方法:自2011年1月至2017年1月,31例局部晚期或轉(zhuǎn)移性胰腺癌患者于中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院接受吉西他濱、奧沙利鉑聯(lián)合口服氟尿嘧啶類藥物治療,排除2例未評價療效的患者,2例失訪患者,共27例患者納入研究。分別按照實體瘤的療效評價標(biāo)準(zhǔn)(RECIST)1.0和國立癌癥研究所毒性判定標(biāo)準(zhǔn)(NCI-CTC)4.0評價療效和毒性。具體給藥方案為:吉西他濱1OOOmg/m~2,化療第一天靜脈滴注;奧沙利鉑85mg/m~2,化療第一天靜脈滴注;口服氟尿嘧啶類藥物:卡培他濱1000mg/m~2,每日兩次,連續(xù)口服八天或替吉奧40mg/m~2,每日兩次,連續(xù)口服八天,每14天為1周期,每4周期評估療效。結(jié)果:接受吉西他濱、奧沙利鉑、口服氟尿嘧啶(卡培他濱或替吉奧)聯(lián)合化療方案的患者中位無進(jìn)展生存時間(mPFS)及中位生存期(mOS)分別為:5.91個月(95%CI:2.24～9.59個月)、11.8個月(95%CI:10.8～12.8個月);客觀緩解率(0RR)為:22.2%;疾病控制率(DCR)為:55.5%。3/4級不良事件包括中性粒細(xì)胞減少7例(25.9%)、腹瀉1例(3.7%)、嘔吐1例(3.7%)、口腔潰瘍1例(3.7%)。結(jié)論:吉西他濱、奧沙利鉑聯(lián)合口服氟尿嘧啶類藥物對局部晚期和轉(zhuǎn)移性胰腺癌一線治療中具有較好的療效及安全性。
[Abstract]:Aim: to observe the efficacy and safety of gemcitabine and oxaliplatin combined with oral fluorouracil in the treatment of pancreatic cancer. Methods: from January 2011 to January 2017, 31 patients with locally advanced or metastatic pancreatic cancer were treated with gemcitabine, oxaliplatin and oral fluorouracil at the Cancer Hospital of the Chinese Academy of Medical Sciences. Two patients without evaluation and two patients without visit were excluded. 27 patients were included in the study. The efficacy and toxicity were evaluated according to (RECIST) 1.0 and NCI-CTC 4.0, respectively. The specific regimens were as follows: gemcitabine 1OOOmg / mc-2, intravenous drip on the first day of chemotherapy, oxaliplatin 85 mg / mm2, intravenous drip on the first day of chemotherapy; Oral fluorouracil drugs: capecitabine 1000mg / mm2, twice a day, or Tegueo 40mg / mt2, twice a day, for eight consecutive days, once every 14 days, every four cycles. Results: gemcitabine, oxaliplatin, The median progression-free survival time (mPFS) and median survival time (mOS) were 5.91 months (95 CI: 2.24 ~ 9.59 months) in patients with oral fluorouracil (capecitabine or tegiro). 11.8 months (95%CI:10.8~12.8 months); Objective remission rate (0RR) was 22. 2%; The disease control rate (DCR) was 55.5 / 3 / 4 adverse events including neutropenia in 7 cases (25.9%), diarrhea in 1 case (3.7%), vomiting in 1 case (3.7%) and oral ulcer in 1 case (3.7%). Conclusion: gemcitabine and oxaliplatin combined with oral fluorouracil are effective and safe in the treatment of advanced and metastatic pancreatic cancer.
【學(xué)位授予單位】：北京協(xié)和醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R735.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 王理偉;陳棟暉;李琦;樓文輝;夏廷毅;潘宏銘;王儉;張智弘;白永瑞;;胰腺癌綜合診治中國專家共識(2014年版)[J];臨床腫瘤學(xué)雜志;2014年04期

，

本文編號：2337135